Granocyte (Lenograstim)

Granocyte is used to reduce the risk of infection in patients whose neutrophil counts are low due to specific medical treatments.

• Management of chemotherapy‑induced neutropenia in adult cancer patients.
• Prevention of febrile neutropenia during high‑dose chemotherapy regimens.
• Support of neutrophil recovery after autologous or allogeneic bone marrow transplantation.
• Treatment of severe neutropenia when rapid hematopoietic stimulation is required.
• Use in patients with congenital neutropenia who have inadequate response to other G‑CSF agents.
• Adjunct therapy in clinical trials evaluating novel chemotherapy protocols.

The safety profile of lenograstim reflects its pharmacologic activity on the bone marrow and immune system.

Common

• Bone pain, especially in the lower back or limbs.
• Mild fever or chills.
• Injection site erythema or discomfort.
• Fatigue or weakness.
• Nausea.

Serious

• Severe allergic reactions such as anaphylaxis.
• Splenic rupture or enlargement.
• Acute respiratory distress syndrome.
• Capillary leak syndrome.
• Unexplained bleeding or bruising.

Healthcare providers should evaluate patient history and clinical status before initiating Granocyte therapy.

• Assess baseline neutrophil count and overall bone‑marrow function.
• Use caution in patients with a history of hypersensitivity to recombinant proteins.
• Monitor for signs of splenic enlargement during treatment.
• Adjust dosing in patients with renal or hepatic impairment as recommended.
• Avoid use in patients with active uncontrolled infections unless benefits outweigh risks.
• Discontinue if severe adverse reactions occur.

Lenograstim may interact with other medications that affect blood cell production or immune responses.

Avoid

• Concurrent use of chemotherapy agents that cause profound myelosuppression without appropriate timing.
• Live vaccines administered during treatment, due to altered immune response.

Use with caution

• Corticosteroids, which may blunt the neutrophil response.
• Immunosuppressive biologics such as anti‑TNF agents.
• Anticoagulants, as rapid neutrophil changes can affect bleeding risk.
• Other colony‑stimulating factors, to prevent overlapping toxicity.